NASDAQ : INCY
Incyte Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 120.39 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 24.54B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 24.46B |
| Enterprise Value | 20.65B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 203.83M |
| Shares Outstanding | 203.83M |
| Shares Change (YoY) | +3.21% |
| Shares Change (QoQ) | -2.39% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 87.16% |
| Float | 171.56M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 61.74 |
| Forward PE | 15.25 |
| PS Ratio | 4.04 |
| Forward PS | 4.07 |
| PB Ratio | 4.35 |
| P/TBV Ratio | 4.49 |
| P/FCF Ratio | 35.46 |
| P/OCF Ratio | 32.60 |
| PEG Ratio | 1.40 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 50.74 |
| EV / Sales | 3.41 |
| EV / EBITDA | 10.06 |
| EV / EBIT | 10.57 |
| EV / FCF | 29.89 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.84 |
| Quick Ratio | 3.54 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.05 |
| Interest Coverage | 828.46 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 7.84% |
| Return on Assets (ROA) | 17.78% |
| Return on Invested Capital (ROIC) | 53.44% |
| Return on Capital Employed (ROCE) | 33.11% |
| Weighted Average Cost of Capital (WACC) | 8.31% |
| Revenue Per Employee | $2.11M |
| Profits Per Employee | $141,846 |
| Employee Count | 2,844 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 24.29 |
Taxes
| Measure | Value |
|---|
| Income Tax | 392.80M |
| Effective Tax Rate | 49.33% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +28.39% |
| 50-Day Moving Average | 120.33 |
| 200-Day Moving Average | 108.13 |
| Relative Strength Index (RSI) | 56.63 |
| Average Volume (20 Days) | 1,841,072 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.03M |
| Short Previous Month | 9.99M |
| Short % of Shares Out | 4.92% |
| Short % of Float | 5.84% |
| Short Ratio (days to cover) | 5.61 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.01B |
| Gross Profit | 3.37B |
| Operating Income | 1.94B |
| Pretax Income | 796.21M |
| Net Income | 403.41M |
| EBITDA | 2.04B |
| EBIT | 1.94B |
| Earnings Per Share (EPS) | $1.94 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.85B |
| Total Debt | 37.41M |
| Net Cash | 3.82B |
| Net Cash Per Share | $18.73 |
| Equity (Book Value) | 5.64B |
| Book Value Per Share | 27.66 |
| Working Capital | 4.08B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 744.99M |
| Capital Expenditures | -60.12M |
| Depreciation & Amortization | 98.44M |
| Net Borrowing | -4.65M |
| Free Cash Flow | 684.87M |
| FCF Per Share | $3.36 |
Margins
| Measure | Value |
|---|
| Gross Margin | 56.02% |
| Operating Margin | 32.22% |
| Pretax Margin | 13.25% |
| Profit Margin | 6.71% |
| EBITDA Margin | 33.86% |
| EBIT Margin | 32.22% |
| FCF Margin | 11.39% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.21% |
| Shareholder Yield | -3.21% |
| Earnings Yield | 1.62% |
| FCF Yield | 2.82% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $131.08 |
| Price Target Difference | 9.22% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 8.43% |
| EPS Growth Forecast (3Y) | 10.17% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 1, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 10.03 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |